A Phase II Study of Preoperative Gemcitabine and Erlotinib Plus Pancreatectomy and Postoperative Gemcitabine and Erlotinib for Patients With Operable Pancreatic Adenocarcinoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 18 Jun 2017
At a glance
- Drugs Erlotinib (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 31 Jul 2015 Planned primary completion date changed from 1 Nov 2015 to 1 Nov 2016 as reported by ClinicalTrials.gov.
- 10 Dec 2014 Last checked against M.D. Anderson Cancer Center record.
- 15 May 2014 Planned primary completion date changed to 1 Nov 2015 as reported by ClinicalTrials.gov.